News

The FDA committee voted nine to one to recommend approval of once-daily Savaysa 60mg dosing regimen for the reduction in risk of stroke and systemic embolic events (SEE)

The early termination of the HSR waiting period satisfies one of the conditions to the closing of the pending acquisition, which remains subject to other customary closing conditions.

AVP-825 is an investigational drug-device combination product developed by OptiNose which uses OptiNose’s patented Bi-Directional Breath Powered technology to deliver a low dose of sumatriptan powder into the

In addition, the USACC has contracted for clinical evaluation of the VesiculoVax Zaire-Ebola virus vaccine to meet the current outbreak in West Africa. The $9.5 million award has

A century later, it also is a symbol of environmental sustainability. Today, ZymoGenetics is among an elite group of laboratories around the world that have earned the U.S.

These waivers are applicable to current or pending New Drug Applications (NDAs) as well as successor products, including those with abuse-deterrent properties and associated labeling claims. In connection

Ofatumumab is a monoclonal antibody designed to target the CD20 molecule found on the surface of chronic lymphocytic leukemia (CLL) cells and normal B lymphocytes. The transfer of

NTCELL is an alginate coated capsule containing clusters of neonatal porcine choroid plexus cells. The open-label trial will evaluate the safety and clinical effects of NTCELL in patients

Construction has already started and the new Diabetes Research House facility is scheduled to be opened in early 2016. Following completion, the new Diabetes Research House will be